Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)

This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

38

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forente stater, 35222
        • Alabama (Site ID: 31788)
        • Ta kontakt med:
    • California
      • Los Angeles, California, Forente stater, 90035
        • University of California, Los Angeles CARE Center (Site ID: 601)
        • Ta kontakt med:
      • San Diego, California, Forente stater, 92103
        • UCSD Antiviral Research Center (Site ID: 701)
        • Ta kontakt med:
      • San Francisco, California, Forente stater, 94110
        • University of California, San Francisco (Site ID: 801)
        • Ta kontakt med:
      • Torrance, California, Forente stater, 90502-2052
        • Harbor University of California Los Angeles Center (Site ID: 603)
        • Ta kontakt med:
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20032
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Northwestern University (Site ID: 2701)
        • Ta kontakt med:
    • Maryland
      • Baltimore, Maryland, Forente stater, 21287
        • Johns Hopkins University (Site ID: 201)
        • Ta kontakt med:
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Massachusetts General Hospital (Site ID: 101)
        • Ta kontakt med:
      • Boston, Massachusetts, Forente stater, 02115
        • Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
        • Ta kontakt med:
    • New Jersey
      • Newark, New Jersey, Forente stater, 07103
        • New Jersey Medical School Clinical Research Center (Site ID: 31786)
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10010
        • Weill Cornell Chelsea (Site ID: 7804)
        • Ta kontakt med:
      • New York, New York, Forente stater, 10010
        • Weill Cornell Uptown (Site ID: 7803)
        • Ta kontakt med:
      • New York, New York, Forente stater, 10032
        • Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
        • Ta kontakt med:
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27599-7215
        • Chapel Hill (Site ID: 3201)
        • Ta kontakt med:
      • Greensboro, North Carolina, Forente stater, 27401-1020
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45267-0405
        • Cincinnati Clinical Research Site (Site ID: 2401)
        • Ta kontakt med:
      • Cleveland, Ohio, Forente stater, 44106
      • Columbus, Ohio, Forente stater, 43210
        • Ohio State University (Site ID: 2301)
        • Ta kontakt med:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15213
        • University of Pittsburgh (Site ID: 1001)
        • Ta kontakt med:
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37204
        • Vanderbilt Therapeutics (VT) (Site ID: 3652)
        • Ta kontakt med:
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Houston Advancing Research Team (Site ID: 31473)
        • Ta kontakt med:
    • Washington
      • Seattle, Washington, Forente stater, 98104
        • University of Washington Positive Research (Site ID: 1401)
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Documented HIV-1 infection

  • Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use

  • HIV-1 RNA >1000 copies/mL within 60 days prior to study entry

  • Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence

  • At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance

  • Adequate laboratory parameters within 60 days prior to study entry:

    • Absolute neutrophil count >600/mm3
    • Hemoglobin ≥7.0 g/dL
    • Platelet count >50,000/μL
    • AST and ALT ≤3 × upper limit of normal
    • Estimated glomerular filtration rate >15 mL/min/1.73 m²
  • For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry

  • Ability and willingness to provide informed consent

  • Connected to a medical clinic with access to HIV care and antiretroviral therapy

Exclusion Criteria:

  • Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
  • Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
  • Child-Pugh Class C cirrhosis
  • No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
  • Prior use of lenacapavir
  • Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
  • Serious medical or psychiatric condition
  • Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
  • Current pregnancy or breastfeeding
  • Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Long-Acting Lenacapavir Plus Long-Acting Cabotegravir

Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation.

Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses.

Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 48
Baseline through Week 48

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
Week 48
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
Week 48
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsramme: Week 48
Week 48
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 96
Baseline through Week 96
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
Tidsramme: Baseline through Week 96
Baseline through Week 96
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 96
Baseline through Week 96
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsramme: Week 96
Week 96
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsramme: Week 96
Week 96
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsramme: Week 96
Week 96
Percentage of on-time long-acting injections
Tidsramme: Through Week 48 and through Week 96
Through Week 48 and through Week 96
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 48 and through Week 96
Baseline through Week 48 and through Week 96
Plasma trough concentrations of lenacapavir and cabotegravir
Tidsramme: Through Week 48 and through Week 96
Through Week 48 and through Week 96
Change in CD4 cell count from baseline
Tidsramme: Week 48 and Week 96
Week 48 and Week 96
Participant-reported treatment satisfaction
Tidsramme: Week 48 and Week 96

HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment.

Week 48 and Week 96
Change in quality-of-life scores from baseline
Tidsramme: Week 48 and Week 96

Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

Week 48 and Week 96
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
Tidsramme: Week 48 and Week 96

Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

Week 48 and Week 96
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
Tidsramme: Baseline through Week 48
Baseline through Week 48
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
Week 48
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
Week 48
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsramme: Week 48
Week 48

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. februar 2028

Primær fullføring (Antatt)

31. august 2029

Studiet fullført (Antatt)

26. oktober 2030

Datoer for studieregistrering

Først innsendt

10. november 2026

Først innsendt som oppfylte QC-kriteriene

10. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • A5431
  • 39159 (Annen identifikator: DAIDS-ES ID)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Individual participant data that underlie results in the publication after deidentification

IPD-delingstidsramme

Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH

Tilgangskriterier for IPD-deling

With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.

For what types of analyses? To achieve aims in the proposal approved by the ACTG.

By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere